

Ing Soo Tiong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1157235/publications.pdf>

Version: 2024-02-01

32
papers

1,703
citations

516710

16
h-index

477307

29
g-index

32
all docs

32
docs citations

32
times ranked

2300
citing authors

#	ARTICLE	IF	CITATIONS
1	Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1277-1284.	1.6	494
2	Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. <i>Blood</i> , 2020, 135, 791-803.	1.4	412
3	Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 3506-3517.	1.6	112
4	Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. <i>Blood</i> , 2017, 130, 2469-2474.	1.4	110
5	Chromosomal Abnormalities and Prognosis in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. <i>Journal of Clinical Oncology</i> , 2019, 37, 2632-2642.	1.6	77
6	Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2369-2375.	3.0	68
7	Venetoclax induces rapid elimination of <i>NPM1</i> mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 192, 1026-1030.	2.5	63
8	Testing probiotic strain <i>Escherichia coli</i> Nissle 1917 (Mutaflor) for its ability to reduce carriage of multidrug-resistant <i>E. coli</i> by elderly residents in long-term care facilities. <i>Journal of Medical Microbiology</i> , 2011, 60, 366-370.	1.8	45
9	Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia. <i>Nature Cancer</i> , 2021, 2, 1204-1223.	13.2	42
10	New drugs creating new challenges in acute myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 903-914.	2.8	39
11	Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1902-1910.	6.4	37
12	Clinical impact of <i>NPM1</i> -mutant molecular persistence after chemotherapy for acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 5107-5111.	5.2	25
13	Adequacy of High-Dose Cefepime Regimen in Febrile Neutropenic Patients with Hematological Malignancies. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5463-5469.	3.2	23
14	Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	22
15	Baseline and treatment-related changes in thrombin generation in patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 941-949.	1.3	21
16	The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study. <i>Oncotarget</i> , 2017, 8, 52269-52280.	1.8	20
17	A Case of Hemophagocytic Lymphohistiocytosis in a Patient with Chronic Lymphocytic Leukemia after Treatment with Fludarabine, Cyclophosphamide, and Rituximab Chemotherapy, with Autopsy Findings. <i>Case Reports in Hematology</i> , 2012, 2012, 1-4.	0.4	14
18	Molecular Patterns of Response and Outcome in the Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT study). <i>Blood</i> , 2018, 132, 333-333.	1.4	14

#	ARTICLE	IF	CITATIONS
19	Cutaneous Plasmablastic Lymphoma in an Immunocompetent Patient with Long-Term Pyrimethamine Use for Essential Thrombocythemia: A Case Report and Literature Review. <i>Case Reports in Hematology</i> , 2013, 2013, 1-6.	0.4	12
20	Apparent JAK2-negative polycythaemia vera due to compound mutations in exon 14. <i>British Journal of Haematology</i> , 2017, 178, 333-336.	2.5	12
21	TWISTING MANE LIVER FOR SUTURELESS VITRECTOMY TROCAR INSERTION TO REDUCE INTRAOPERATIVE INTRAOCULAR PRESSURE RISE. <i>Retina</i> , 2011, 31, 887-892.	1.7	7
22	Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms. <i>American Journal of Hematology</i> , 2022, 97, 1013-1022.	4.1	7
23	Nonbacterial Thrombotic Endocarditis with ST-elevation Myocardial Infarction Treated with Percutaneous Coronary Aspiration Thrombectomy. <i>Heart Lung and Circulation</i> , 2013, 22, 386-389.	0.4	6
24	Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 493-496.	1.3	5
25	Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies. <i>Blood Cancer Journal</i> , 2018, 8, 84.	6.2	5
26	The Natural History of NPM1MUT Measurable Residual Disease (MRD) Positivity after Completion of Chemotherapy in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 25-27.	1.4	4
27	Treatment practice and outcomes in FLT3-mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals. <i>Leukemia and Lymphoma</i> , 2020, 61, 848-854.	1.3	3
28	Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm- overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement. <i>Pathology</i> , 2022, , .	0.6	2
29	Primary endometrial uterine Burkitt lymphoma in a 65-year-old woman. <i>Gynecologic Oncology Reports</i> , 2015, 13, 30-32.	0.6	1
30	Real-world tolerability of venetoclax-based maintenance therapy with azole antifungal prophylaxis for acute myeloid leukemia in remission. <i>Leukemia Research</i> , 2022, , 106837.	0.8	1
31	High Sensitivity Detection of FLT3-ITD Measurable Residual Disease By Deep Sequencing Prior to Hematopoietic Cell Transplant Is Highly Prognostic for Outcome in Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 2364-2364.	1.4	0
32	Outcomes of nonmyeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission. <i>Internal Medicine Journal</i> , 2021, 51, 1954-1958.	0.8	0